STENTYS Wins Large Regional Tender in Middle East

Regulatory News:

STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing^® stent to treat acute myocardial infarction (AMI), today announced that the 2014 SGH tender has awarded more than 1,000 coronary stents to STENTYS.

The SGH Tender is a group purchasing program that serves the Ministries of Health in the six GCC members states: United Arab Emirates, Kingdom of Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, State of Qatar and State of Kuwait. It is renewed every year for a period of one year.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, stated: "The successful outcome of this tender is a concrete result of our commercial strategy in the Middle East. It started by establishing ties with strong local partners and was accelerated recently with the opening of a branch office in Dubai. We are very satisfied with this strategy and will continue its implementation to serve cardiologists worldwide.”

• Upcoming financial publication

STENTYS expects to publish its revenues for the 3^rd quarter on October 23, 2014.

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

STENTYS is listed on Comp. B of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT